Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cingulate Inc.CING · Entity 6983 | EVP & Chief Commercial Officer | July 16, 2026 | July 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cingulate Inc.
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2036-07-16 | Direct | 67,000 |
Reported balance
After 2026-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 67,000 · Balance 67,000 F1: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. |
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2036-07-16 | Direct | 33,000 |
Reported balance
After 2026-07-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-16 · Grant · Acquired 33,000 · Balance 33,000 F1: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. F2: Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027. F3: If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date.
F2: Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027.
F3: If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 20, 2026 23:35 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 33,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033970 · ownership.xml · derivative · entry 2 Downey Bryan Wade · CIK 0002095821 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. F2 · derivative.exercise_date: Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027. F3 · derivative.expiration_date: If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:35 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 67,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033970 · ownership.xml · derivative · entry 1 Downey Bryan Wade · CIK 0002095821 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| November 03, 2025 Filed Nov 10, 2025 23:02 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001493152-25-021580 · ownership.xml · derivative · entry 1 Downey Bryan Wade · CIK 0002095821 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-11-03 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.